About us

Scintomics Molecular, Applied Theranostics Technologies (SCI-att) is a growing player in the radiopharmaceutical business with a particular strategic emphasis on providing unrestricted supply and support of proprietary and innovative tracer technology and non-IP protected precursors.

The well-known GRP Module Series became part of SCI-att in April 2020 when SCI-att took over the Module business from its parent company Scintomics, which has been selling and installing fully automated production systems for established radio-pharmaceuticals in clinical facilities around the world since 2006.

Happy Clients
Years In Business
Cups of Coffee

2Quart Medical 2Quart Medical
Mezenhof 83
1742 Schagen
NOORD-HOLLAND / Netherlands
CardiRad CardiRad Sweden AB
Karusellplan 8
12631 Hägersten

DSD Pharma DSD Pharma GmbH
Schuhmeierstraße 24
1140 Purkersdorf
Global Medical Solutions Global Medical Solutions Pty Ltd
253 Princes Hwy
2205 Arncliffe, NSW
Health Technologies Health Technologies Sp. Z.o.o.
Chocimska 20/101
00-791 Warszawa
Imaxeon Imaxeon Pty. Ltd.
Unit 1, 38-46 South Street
Rydalmere NSW 2116
MediRay Mediray GPC
Aetideon 2 & Mesogeion 224
15561 Holargos
Nepha Nepha Tibbi Cihazlar SAN.VE TIC. A.S
Sedat Simavi Sok, Gul Apt 21A
06550 Çankaya/Ankara,
Imaxeon QT Instruments (S) Pte. Ltd.
192 Pandan Loop SGP
#06-20 Pantech Business Hub
128381 Singapore
Tecnasa TECNASA, Tecnologias Asociadas
c/ Primera, 27
28016 Madrid
Vega Medical VEGA Medical
Boul. Bulgaria 109, fl.2, office 2.6 Vertigo Tower
1404 Sofia

Our Scintomics/att History


Founded by Prof. H. J. Wester (TUM)

Founded by Prof. H. J. Wester (TUM)

Start of:

Hotbox series & Gallelut (still running at several customer sites)


Start of:

Start of:

GRP Modules for GMP production and radiopharmaceutical research (in the meantime over 200 installed systems worldwide)

Innovative tracer techniques and Radiopharmaceuticals for Imaging and Therapy, (IP protected in several countries)


Scintomics Molecular, att GmbH founded by Scintomics GmbH

New portfolio with cassettes, consumables and precursors, such as PSMA I&T (patent protected in several EU countries and Australia) and next generation PSMA inhibitors for radioligand therapy.


att takes over Module Business from Scintomics

att takes over Module Business from Scintomics

Start of:

new siGRP-Module:

for production of the two SiFA-based radiopharmaceuticals [F-18]siPSMA and [F-18]SiFAlin-TATE – ready to compete with Ga-68 !

Our Gallery


Scintomics, a privately held company based near Munich/Germany, is committed to targeted theranostics and corresponding radiopharmaceutical technologies. Its strong focus towards personalized cancer care is reflected by an exceptional and continuously growing portfolio of innovative tracer technologies and the clinical development of Theranostic through subsidiaries, joint ventures and alliances.


Its subsidiary Scintomics Molecular, Applied Theranostics technologies continues Scintomics ́ radiopharmaceutical business segment in an independent manner with a particular strategic emphasis on providing unrestricted supply and support of Scintomics proprietary and innovative tracer technology and non-IP protected precursors as well as the more than 15 year experience in Synthesis Modules.